The lawsuit alleges the same type of failure to warn of side effects such as Gastroparesis, Stomach Paralysis, Ileus, Gallbladder issues, and Gastric Intestinal Obstruction
As we discussed above, the selected treatments must be targeted and effective for the patients specific ARDS phenotype
It filled a genuine gap when GLP-1s were impossible to find, and it continues to serve patients with needs that FDA-approved medications cant meet
That is what we have started this week with tirzepatide. Trial protocols call for half of the 1,000 participants to receive a placebo, inert doses that have no effect, rather than the active drug, creating a control group that is critical to obtaining scientifically valid results
Recent Developments 13
A prospective study of patients switching directly from GLP-1 medications to tirzepatide 5 mg found that only about 13% experienced GI side effects, and just 2% discontinued due to adverse events